4.6 Article

SUMOylation of Tissue Transglutaminase as Link between Oxidative Stress and Inflammation

Journal

JOURNAL OF IMMUNOLOGY
Volume 183, Issue 4, Pages 2775-2784

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.0900993

Keywords

-

Categories

Funding

  1. European Institute
  2. Cancer Research UK
  3. Rothschild Trust
  4. Coeliac UK
  5. Regione Campania [L.229/99]
  6. Associazione Italiana Celiachia Puglia [N.1400/07]

Ask authors/readers for more resources

Cystic fibrosis (CF) is a monogenic disease caused by mutations in the CIF transmembrane conductance regulator (CFTR) gene. CF is characterized by chronic bacterial lung infections and inflammation, and we have previously reported that tissue transglutaminase (TG2), a multifunctional enzyme critical to several diseases, is constitutively up-regulated in CIF airways and drives chronic inflammation. Here, we demonstrate that the generation of an oxidative stress induced by CFTR-defective function leads to protein inhibitor of activated STAT (PIAS)y-mediated TG2 SUMOylation and inhibits TG2 ubiquitination and proteasome degradation, leading to sustained TG2 activation. This prevents peroxisome proliferator-activated receptor (PPAR)gamma and IkB alpha SUMOylation, leading to NF-kappa B activation and to an uncontrolled inflammatory response. Cellular homeostasis can be restored by small ubiquitin-like modifier (SUMO)-1 or PIASy gene silencing, which induce TG2 ubiquitination and proteasome degradation, restore PPAR gamma SUMOylation, and prevent IkB alpha cross-linking and degradation, thus switching off inflammation. Manganese superoxide dismutase overexpression as well as the treatment with the synthetic superoxide dismutase mimetic EUK-134 control PIASy-TG2 interaction and TG2 SUMOylation. TG2 inhibition switches off inflammation in vitro as well as in vivo in a homozygous F508del-CFTR mouse model. Thus, TG2 may function as a link between oxidative stress and inflammation by driving the decision as to whether a protein should undergo SUMO-mediated regulation or degradation. Targeting TG2-SUMO interactions might represent a new option to control disease evolution in CIF patients as well as in other chronic inflammatory diseases, neurodegenerative pathologies, and cancer. The Journal of Immunology, 2009, 183: 2775-2784.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available